Standard

Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study. / Zurochka , A.; Dobrinina, M.; Zurochka , V. et al.
In: Vaccines, Vol. 9, No. 6, 627, 06.2021.

Research output: Contribution to journal › Article › peer-review

Harvard

Zurochka , A, Dobrinina, M, Zurochka , V, Hu , D, Solovyev , A, Ryabova , L, Kritsky, I, Ibragimov, R & Sarapultsev, A 2021, 'Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study', Vaccines, vol. 9, no. 6, 627. https://doi.org/10.3390/vaccines9060627

APA

Zurochka , A., Dobrinina, M., Zurochka , V., Hu , D., Solovyev , A., Ryabova , L., Kritsky, I., Ibragimov, R., & Sarapultsev, A. (2021). Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study. Vaccines, 9(6), [627]. https://doi.org/10.3390/vaccines9060627

Vancouver

Zurochka A, Dobrinina M, Zurochka V, Hu D, Solovyev A, Ryabova L et al. Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study. Vaccines. 2021 Jun;9(6):627. doi: 10.3390/vaccines9060627

Author

Zurochka , A. ; Dobrinina, M. ; Zurochka , V. et al. / Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study. In: Vaccines. 2021 ; Vol. 9, No. 6.

BibTeX

@article{be455301f8ca49779d8d70b56541e647,
title = "Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study",
keywords = "Antibody, COVID-19, Focus groups, Global health, High-risk groups, Seroprevalence, global health, POPULATION, IMMUNITY, antibody, seroprevalence, IGG, RESPONSES, high-risk groups, focus groups, INFECTION, SEX-DIFFERENCES",
author = "A. Zurochka and M. Dobrinina and V. Zurochka and D. Hu and A. Solovyev and L. Ryabova and Igor Kritsky and Roman Ibragimov and Alexey Sarapultsev",
note = "Funding Information: The reported study was funded by RFBR and NSFC (project No.20-515-55003), by the NSFC (project No. 82161138003), and partly by the Government contract of the Institute of Immunology and Physiology (AAAA-A21-121012090090-9).",
year = "2021",
month = jun,
doi = "10.3390/vaccines9060627",
language = "English",
volume = "9",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

RIS

TY - JOUR

T1 - Seroprevalence of sars-cov-2 antibodies in symptomatic individuals is higher than in persons who are at increased risk exposure: The results of the single-center, prospective, cross-sectional study

AU - Zurochka , A.

AU - Dobrinina, M.

AU - Zurochka , V.

AU - Hu , D.

AU - Solovyev , A.

AU - Ryabova , L.

AU - Kritsky, Igor

AU - Ibragimov, Roman

AU - Sarapultsev, Alexey

N1 - Funding Information: The reported study was funded by RFBR and NSFC (project No.20-515-55003), by the NSFC (project No. 82161138003), and partly by the Government contract of the Institute of Immunology and Physiology (AAAA-A21-121012090090-9).

PY - 2021/6

Y1 - 2021/6

KW - Antibody

KW - COVID-19

KW - Focus groups

KW - Global health

KW - High-risk groups

KW - Seroprevalence

KW - global health

KW - POPULATION

KW - IMMUNITY

KW - antibody

KW - seroprevalence

KW - IGG

KW - RESPONSES

KW - high-risk groups

KW - focus groups

KW - INFECTION

KW - SEX-DIFFERENCES

UR - http://www.scopus.com/inward/record.url?scp=85108624514&partnerID=8YFLogxK

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=000666538000001

UR - https://elibrary.ru/item.asp?id=46910672

U2 - 10.3390/vaccines9060627

DO - 10.3390/vaccines9060627

M3 - Article

AN - SCOPUS:85108624514

VL - 9

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 6

M1 - 627

ER -

ID: 22222119